Pharmabiz

SpectronRx commences mass production of high-purity Actinium-225, to strengthen global supply for cancer therapies

SpectronRx commences mass production of high-purity Actinium-225, to strengthen global supply for cancer therapies: Indiana Saturday, November 1, 2025, 15:00 Hrs [IST] SpectronRx, ...
Pharmabiz

Ascletis selects ASC36 for clinical development; plans to submit IND to US FDA in second quarter of 2026

Ascletis selects ASC36 for clinical development; plans to submit IND to US FDA in second quarter of 2026: Hong Kong Saturday, November 1, 2025, 18:00 Hrs [IST] Ascletis Pharma Inc ...
Pharmabiz

PharmaDrug executes definitive agreement with Canurta Limited Partnership to buy 40% equity interest in Canurta

PharmaDrug executes definitive agreement with Canurta Limited Partnership to buy 40% equity interest in Canurta: Toronto, Ontario Saturday, November 1, 2025, 17:00 Hrs [IST] Pharm ...
Pharmabiz

ProImmune launches ProVE SL self-loading MHC Class I monomers to improve T cell research flexibility

ProImmune launches ProVE SL self-loading MHC Class I monomers to improve T cell research flexibility: Oxford, England Saturday, November 1, 2025, 14:00 Hrs [IST] ProImmune Ltd, a ...
Pharmabiz

Novotech maps global growth in radiopharmaceutical trials

Novotech, a leading global clinical research organization (CRO) and scientific advisory partner, released a new white paper detailing the rapid rise of therapeutic radiopharmaceutical research and the ...
Pharmabiz

Codexis & Nitto Denko Avecia ink evaluation agreement to explore Codexis’s ECO Synthesis Manufacturing Platform for therapeutic siRNA manufacturing

Codexis & Nitto Denko Avecia ink evaluation agreement to explore Codexis’s ECO Synthesis Manufacturing Platform for therapeutic siRNA manufacturing: Redwood City, California Sat ...
Pharmabiz

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...
Pharmabiz

Novo Nordisk submits proposal to buy Metsera

Bagsværd, Denmark Saturday, November 1, 2025, 12:00 Hrs [IST] Novo Nordisk, a leading global healthcare company founded in 1923 and ...
Pharmabiz

Cellectricon broadens discovery capabilities with launch of Neurotoxicity Testing Services

Cellectricon broadens discovery capabilities with launch of Neurotoxicity Testing Services: Molndal, Sweden Saturday, November 1, 2025, 11:00 Hrs [IST] Cellectricon, a services pr ...
Pharmabiz

KDPMA asserts need for Pharma Park & its integration into Karnataka's Biotech sector to boost visibility

Nandita Vijayasimha, Bengaluru Saturday, November 1, 2025, 08:00 Hrs [IST] ...
Opinion
PharmabizOpinion

THE HEARTLESS COUNTERFEITERS

But, the heartless counterfeiters have gone one step further as recent investigations by the drug authorities have exposed a clandestine operation involving the inter-state distribution of counterfeit ...
Pharmabiz

Need to redefine GLP-1 therapy to adopt metabolism first path towards diabetes care: Expert

Need to redefine GLP-1 therapy to adopt metabolism first path towards diabetes care: Expert: Shardul Nautiyal, Mumbai Saturday, November 1, 2025, 08:00 Hrs [IST] There is a need t ...